Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A generous gift from The Sir John Ritblat Family Foundation has enabled the creation of a new Professorship in Mindfulness and Psychological Science. The post, which is to be held by the Director of the Oxford Mindfulness Centre, promises to transform our understanding of the link between mind and body, and lead the world into a new era of human health.

None
A MINDFULNESS-BASED COGNITIVE THERAPY TRAINING SESSION LED BY WILLEM KUYKEN AND MARK WILLIAMS (SHANGHAI, 2018)

Sometimes described as 'the art of conscious living', mindfulness is a natural capacity for moment-by-moment awareness – a practice that enables us to change the way we think and feel about our experiences by developing attentiveness to the present. In recent years, mindfulness has become a recognised form of treatment for both physical and emotional health in mainstream medicine.

Oxford now sits at the forefront of mindfulness research and teaching internationally. Through the Oxford Mindfulness Centre (OMC) – established in 2008 within the Department of Psychiatry – researchers combine ancient wisdom with rigorous contemporary science to better understand the practice's potential for improving health and wellbeing.

The centre's current research agenda has been developed in close collaboration with policy-makers, and the OMC is now undertaking major studies into the promise of mindfulness in education, the workplace and criminal justice systems. The establishment of a permanent post in mindfulness – the first of its kind globally – will enable Oxford to build a permanent research and training centre, and continue to be a leader in this field.

Read more (Oxford Thinking website)

Similar stories

Risk of rare blood clotting higher for COVID-19 than for vaccines

Coronavirus COVID-19 Research

COVID-19 leads to a several-times higher risk of cerebral venous thrombosis (CVT) blood clots than current COVID-19 vaccines.

Alternating vaccines trial expands to include two additional vaccines

Clinical Trials Coronavirus COVID-19 General

Researchers running the Com-Cov study, launched in February to investigate alternating doses of the Oxford-AstraZeneca vaccine and the Pfizer vaccine, have today announced that the programme will be extended to include the Moderna and Novavax vaccines in a new study.

Oxford medical students launch flagship raffle in aid of NHS heroes and lifesaving medical equipment

General

Tingewick, a society formed of medical students from Oxford University, are hosting a virtual charity raffle. With over 70 amazing prizes, ranging from Truck festival tickets to restaurant vouchers to bags of books and even a bike, the raffle is an exciting way to celebrate lockdown lifting by supporting many wonderful Oxfordshire businesses whilst raising lots of money for charity.

Asthma drug budesonide shortens recovery time in non-hospitalised patients with COVID-19

Clinical Trials Coronavirus COVID-19 Research

Inhaled budesonide, a common corticosteroid, is the first widely available, inexpensive drug found to shorten recovery times in COVID-19 patients aged over 50 who are treated at home and in other community settings, reports the PRINCIPLE trial in 1,779 participants.

UK and EU regulators conclude benefits of vaccination continue to outweigh the risks

Coronavirus COVID-19 General

Today, the medical regulators in the UK and Europe have announced their conclusions from their reviews of very rare cases of unusual blood clots in people who have received the Oxford-AstraZeneca coronavirus vaccine.

Link between COVID-19 infection and subsequent mental health and neurological conditions found

Coronavirus COVID-19 General Research

One in three COVID-19 survivors received a neurological or psychiatric diagnosis within six months of infection with the SARS-CoV-2 virus, an observational study of more than 230,000 patient health records published in The Lancet Psychiatry journal estimates. The study looked at 14 neurological and mental health disorders.